Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Dabrafenib/trametinib bij melanoom na prijsonderhandeling in basispakket
jun 2020 | Dermato-oncologie